Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Alirocumab 150 MG/ML [Praluent]
Regeneron UK Limited
Hemodialysis
1 trial -
Alirocumab SAR236553
Regeneron UK Limited
Hypercholesterolaemia
1 trial -
Alisertib
Takeda
Relapsed Peripheral T-Cell Lymphoma
1 trial -
Aliskiren
Novartis Pharmaceuticals
Acute Decompensated Heart Failure
1 trial -
Almonertinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer Metastatic
1 trial -
Alogliptin
Takeda
Diabetes Mellitus
9 trials -
Alogliptin
Takeda
Type 2 Diabetes Mellitus
5 trials -
Alogliptin Benzoate
Takeda
Diabetes Mellitus, Type 2
1 trial -
Alogliptin and glimepiride
Takeda
Type 2 Diabetes Mellitus
2 trials -
Alogliptin and glyburide
Takeda
Diabetes Mellitus
1 trial -
Alogliptin and insulin
Takeda
Diabetes Mellitus
1 trial -
Alogliptin and metformin
Takeda
Type 2 Diabetes Mellitus
1 trial -
Alogliptin and metformin
Takeda
Diabetes Mellitus
1 trial -
Alogliptin and pioglitazone
Takeda
Type 2 Diabetes Mellitus
2 trials -
Alogliptin and pioglitazone
Takeda
Diabetes Mellitus
2 trials -
Alogliptin and voglibose
Takeda
Type 2 Diabetes Mellitus
2 trials -
Alyftrek 125 mg/50 mg/10 mg film-coated tablets, VX-121/VX-661/VX-561 Film-coated tablet
Vertex Pharmaceuticals (Australia) Pty.
Cystic Fibrosis
1 trial -
Ambrisentan Viatris 5 mg film-coated tablets, Placebo de AMBRISENTAN VIATRIS 5 mg - composition: cellulose microcristalline; lactose monohydraté; silice colloïdale anhydre; stéarate de magnésium (vegetable origin); opadry II 85G94065 PINK; eau purifiée, TADALAFIL
Pari Pharma GmbH
Pulmonary arterial hypertension
1 trial -
Ambroxol Hydrochloride 30 mg tablet - 9 mg/kg/day
Ultragenyx UK Limited
Sanfilippo Syndrome
1 trial -
Amchafibrin
Lxo Ireland Designated Activity Company
Osteoarthritis, Knee
1 trial -
Amifampridine Phosphate
CATALYST PHARMACEUTICALS, INC.
Lambert Eaton Myasthenic Syndrome
2 trials -
Amifampridine Phosphate
CATALYST PHARMACEUTICALS, INC.
Myasthenia Gravis, MuSK
1 trial -
Amifampridine Phosphate
CATALYST PHARMACEUTICALS, INC.
Myasthenia Gravis, Generalized
1 trial -
Amikacin Inhalation Solution (BAY41-6551)
Nektar Therapeutics UK Limited
Pneumonia, Bacterial
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources